share_log

EF Hutton Initiates Coverage On VolitionRX With Buy Rating, Announces Price Target of $4.5

Benzinga ·  Oct 30, 2023 10:58

EF Hutton analyst Tim Moore initiates coverage on VolitionRX (AMEX:VNRX) with a Buy rating and announces Price Target of $4.5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment